Randi R. Mathiesen
Oslo University Hospital
10 Papers
3 Citations
Randi R. Mathiesen is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Breast cancer & Circulating tumor cell. The author has an hindex of 6, co-authored 7 publications. Previous affiliations of Randi R. Mathiesen include Akershus University Hospital.
Chat about Author
Papers
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
François-Clément Bidard,Stefan Michiels,Sabine Riethdorf,Volkmar Mueller,Laura J. Esserman,Anthony Lucci,Bjørn Naume,Bjørn Naume,Jun Horiguchi,Rafael Gisbert-Criado,Stefan Sleijfer,Masakazu Toi,José A. García-Sáenz,Andreas D. Hartkopf,Daniele Generali,Françoise Rothé,Jeffrey B. Smerage,Laura Muinelo-Romay,Justin Stebbing,Patrice Viens,Mark Jesus M. Magbanua,Carolyn S. Hall,Olav Engebraaten,Daisuke Takata,Jose Vidal-Martinez,Wendy Onstenk,Noriyoshi Fujisawa,Eduardo Díaz-Rubio,Florin-Andrei Taran,Maria Rosa Cappelletti,Michail Ignatiadis,Charlotte Proudhon,Denise M. Wolf,Jessica B. Bowman Bauldry,Elin Borgen,Rin Nagaoka,Vicente Carañana,Jaco Kraan,M. Maestro,Sara Y. Brucker,Karsten Weber,Fabien Reyal,Dominic Amara,Mandar Karhade,Randi R. Mathiesen,Hideaki Tokiniwa,Antonio Llombart-Cussac,Alessandra Meddis,Paul Blanche,Koenraad d'Hollander,Paul Cottu,John W. Park,Sibylle Loibl,Aurélien Latouche,Jean-Yves Pierga,Klaus Pantel +55 more
TL;DR: Adding CTC detection before NCT increased the prognostic ability of multivariable prognostic models for overall survival, distant disease-free survival, and locoregional relapse-free interval and complements current prognosis models based on tumor characteristics and response to therapy.
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing.
Jonas Demeulemeester,Jonas Demeulemeester,Parveen Kumar,Parveen Kumar,Elen K. Møller,Silje Nord,David C. Wedge,April Peterson,April Peterson,Randi R. Mathiesen,Randi R. Mathiesen,Renathe Fjelldal,Masoud Zamani Esteki,Koen Theunis,Elia Fernandez Gallardo,A. Jason Grundstad,Elin Borgen,Lars Oliver Baumbusch,Anne Lise Børresen-Dale,Kevin P. White,Vessela N. Kristensen,Vessela N. Kristensen,Peter Van Loo,Peter Van Loo,Thierry Voet,Thierry Voet,Bjørn Naume,Bjørn Naume +27 more
TL;DR: In this article, single-cell sequencing was applied to identify and trace the origin of disseminated tumor cells (DTCs) in breast cancer, and the authors found that 53% of the single cells morphologically classified as tumor cells are DTCs disseminating from the observed tumor.
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
Randi R. Mathiesen,Elin Borgen,Anne Renolen,Erik Løkkevik,Jahn M. Nesland,Jahn M. Nesland,Gun Anker,Gun Anker,Bjørn Østenstad,Steinar Lundgren,Terje Risberg,Ingvil Mjaaland,Gunnar Kvalheim,Per Eystein Lønning,Per Eystein Lønning,Bjørn Naume,Bjørn Naume +16 more
TL;DR: The results supports the potential use of DTC analysis as a monitoring tool during follow up, for selection of patients to secondary treatment intervention within clinical trials and evaluates their prognostic impact.
Next-generation sequencing of disseminated tumor cells
Elen K. Møller,Elen K. Møller,Parveen Kumar,Thierry Voet,Thierry Voet,April Peterson,Peter Van Loo,Peter Van Loo,Randi R. Mathiesen,Renathe Fjelldal,Jason Grundstad,Elin Borgen,Lars Oliver Baumbusch,Lars Oliver Baumbusch,Bjørn Naume,Bjørn Naume,Bjørn Naume,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Kevin P. White,Silje Nord,Silje Nord,Vessela N. Kristensen,Vessela N. Kristensen,Vessela N. Kristensen +24 more
TL;DR: The analyses allow insight into tumor cell dissemination and show ongoing copy-number evolution in DTCs compared to the primary tumors, indicating that the DTC underwent further evolution at the copy- number level.
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
N. K. Andresen,Andreas Hagen Røssevold,Claire Quaghebeur,Bjørnar Gilje,Beate Boge,Andrea Gombos,Ragnhild Sørum Falk,Randi R. Mathiesen,Lars Julsrud,Øystein Garred,Hege G. Russnes,Ragnhild Reehorst Lereim,Sudhir Kumar Chauhan,Ole Christian Lingjærde,Claire Dunn,Bjørn Naume,Jon Amund Kyte +16 more
TL;DR: The addition of ipi/nivo to chemotherapy increased toxicity without improving efficacy and a numerical PFS advantage was observed for patients with a high Treg gene signature in tumor.
4